• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

    1.350 +0.030 (+2.27%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Pliant Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
    In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso... 
    Via MarketMinute
    News headline image
    Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
    Selected for oral presentation at Clinical Trials Mini Symposium 
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Keep an eye on the top gainers and losers in Thursday's session. ↗
    Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session. 
    Via Chartmill
    News headline image
    Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Get insights into the top gainers and losers of Friday's after-hours session. ↗
    Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
    Via Chartmill
    News headline image
    Pliant Therapeutics Provides Update on BEACON-IPF
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types ↗
    Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial. 
    Via Benzinga
    News headline image
    Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    What's going on in today's after hours session ↗
    After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
    Via Chartmill
    News headline image
    INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.